Citigroup Inc Spero Therapeutics, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.68 - $2.2 $9,429 - $30,507	-13,867 Reduced 96.55%	495 $1,000
Q2 2022 Aug 10, 2022	BUY	$0.74 - $7.44 $9,457 - $95,090	12,781 Added 808.41%	14,362 $11,000
Q1 2022 May 12, 2022	SELL	$7.87 - $15.15 $246,512 - $474,543	-31,323 Reduced 95.2%	1,581 $14,000
Q4 2021 Feb 10, 2022	BUY	$13.09 - $18.77 $220,160 - $315,692	16,819 Added 104.56%	32,904 $527,000
Q3 2021 Nov 10, 2021	BUY	$13.03 - $19.51 $209,587 - $313,818	16,085 New	16,085 $296,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.